1165P Cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer: A prospective, double-cohort, multi-center, open-label, phase II clinical study (AK001)

作者：Minhua Zheng, Honglin Gu, Jian Zhou, J. Wang, Lu Liu, Yun Zhou, Bo Pan, Qianming Chen, Weilan Ye, Yan Ding, Lei Zhou, Lirong Sun, Xun Cao, Jin‐Xin Bei · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.1801 · 被引用次数：1 · 研究领域：HER2/EGFR in Cancer Research、Cancer Immunotherapy and Biomarkers、Endometrial and Cervical Cancer Treatments